351 related articles for article (PubMed ID: 12941910)
1. Assorted mutations in the envelope gene of simian immunodeficiency virus lead to loss of neutralization resistance against antibodies representing a broad spectrum of specificities.
Johnson WE; Sanford H; Schwall L; Burton DR; Parren PW; Robinson JE; Desrosiers RC
J Virol; 2003 Sep; 77(18):9993-10003. PubMed ID: 12941910
[TBL] [Abstract][Full Text] [Related]
2. Ability of the V3 loop of simian immunodeficiency virus to serve as a target for antibody-mediated neutralization: correlation of neutralization sensitivity, growth in macrophages, and decreased dependence on CD4.
Means RE; Matthews T; Hoxie JA; Malim MH; Kodama T; Desrosiers RC
J Virol; 2001 Apr; 75(8):3903-15. PubMed ID: 11264379
[TBL] [Abstract][Full Text] [Related]
3. Characterization of neutralization epitopes of simian immunodeficiency virus (SIV) recognized by rhesus monoclonal antibodies derived from monkeys infected with an attenuated SIV strain.
Cole KS; Alvarez M; Elliott DH; Lam H; Martin E; Chau T; Micken K; Rowles JL; Clements JE; Murphey-Corb M; Montelaro RC; Robinson JE
Virology; 2001 Nov; 290(1):59-73. PubMed ID: 11883006
[TBL] [Abstract][Full Text] [Related]
4. A replication-competent, neutralization-sensitive variant of simian immunodeficiency virus lacking 100 amino acids of envelope.
Johnson WE; Morgan J; Reitter J; Puffer BA; Czajak S; Doms RW; Desrosiers RC
J Virol; 2002 Mar; 76(5):2075-86. PubMed ID: 11836385
[TBL] [Abstract][Full Text] [Related]
5. Removal of N-linked glycosylation sites in the V1 region of simian immunodeficiency virus gp120 results in redirection of B-cell responses to V3.
Cole KS; Steckbeck JD; Rowles JL; Desrosiers RC; Montelaro RC
J Virol; 2004 Feb; 78(3):1525-39. PubMed ID: 14722307
[TBL] [Abstract][Full Text] [Related]
6. Simian immunodeficiency virus engrafted with human immunodeficiency virus type 1 (HIV-1)-specific epitopes: replication, neutralization, and survey of HIV-1-positive plasma.
Yuste E; Sanford HB; Carmody J; Bixby J; Little S; Zwick MB; Greenough T; Burton DR; Richman DD; Desrosiers RC; Johnson WE
J Virol; 2006 Mar; 80(6):3030-41. PubMed ID: 16501112
[TBL] [Abstract][Full Text] [Related]
7. Selection for neutralization resistance of the simian/human immunodeficiency virus SHIVSF33A variant in vivo by virtue of sequence changes in the extracellular envelope glycoprotein that modify N-linked glycosylation.
Cheng-Mayer C; Brown A; Harouse J; Luciw PA; Mayer AJ
J Virol; 1999 Jul; 73(7):5294-300. PubMed ID: 10364275
[TBL] [Abstract][Full Text] [Related]
8. Antigenic variation of SIV: mutations in V4 alter the neutralization profile.
Kinsey NE; Anderson MG; Unangst TJ; Joag SV; Narayan O; Zink MC; Clements JE
Virology; 1996 Jul; 221(1):14-21. PubMed ID: 8661410
[TBL] [Abstract][Full Text] [Related]
9. Simian immunodeficiency virus mutants resistant to serum neutralization arise during persistent infection of rhesus monkeys.
Burns DP; Collignon C; Desrosiers RC
J Virol; 1993 Jul; 67(7):4104-13. PubMed ID: 8510218
[TBL] [Abstract][Full Text] [Related]
10. Identification of Novel Structural Determinants in MW965 Env That Regulate the Neutralization Phenotype and Conformational Masking Potential of Primary HIV-1 Isolates.
Qualls ZM; Choudhary A; Honnen W; Prattipati R; Robinson JE; Pinter A
J Virol; 2018 Mar; 92(5):. PubMed ID: 29237828
[TBL] [Abstract][Full Text] [Related]
11. Infectivity and neutralization of simian immunodeficiency virus with FLAG epitope insertion in gp120 variable loops.
Laird ME; Desrosiers RC
J Virol; 2007 Oct; 81(20):10838-48. PubMed ID: 17686865
[TBL] [Abstract][Full Text] [Related]
12. Analysis of SIVmac Envelope-Specific Antibodies Selected Through Phage Display.
Ita S; Agostinho MR; Sullivan K; Yub Han S; Akleh R; Johnson WE; Fofana IBF
AIDS Res Hum Retroviruses; 2017 Aug; 33(8):869-879. PubMed ID: 28075174
[TBL] [Abstract][Full Text] [Related]
13. Characterization and Implementation of a Diverse Simian Immunodeficiency Virus SIVsm Envelope Panel in the Assessment of Neutralizing Antibody Breadth Elicited in Rhesus Macaques by Multimodal Vaccines Expressing the SIVmac239 Envelope.
Kilgore KM; Murphy MK; Burton SL; Wetzel KS; Smith SA; Xiao P; Reddy S; Francella N; Sodora DL; Silvestri G; Cole KS; Villinger F; Robinson JE; Pulendran B; Hunter E; Collman RG; Amara RR; Derdeyn CA
J Virol; 2015 Aug; 89(16):8130-51. PubMed ID: 26018167
[TBL] [Abstract][Full Text] [Related]
14. Simian immunodeficiency virus (SIV) envelope-specific Fabs with high-level homologous neutralizing activity: recovery from a long-term-nonprogressor SIV-infected macaque.
Glamann J; Burton DR; Parren PW; Ditzel HJ; Kent KA; Arnold C; Montefiori D; Hirsch VM
J Virol; 1998 Jan; 72(1):585-92. PubMed ID: 9420262
[TBL] [Abstract][Full Text] [Related]
15. The V1/V2 domain of gp120 is a global regulator of the sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon infection.
Pinter A; Honnen WJ; He Y; Gorny MK; Zolla-Pazner S; Kayman SC
J Virol; 2004 May; 78(10):5205-15. PubMed ID: 15113902
[TBL] [Abstract][Full Text] [Related]
16. Fine analysis of humoral antibody response to envelope glycoprotein of SIV in infected and vaccinated macaques.
Silvera P; Flanagan B; Kent K; Rud E; Powell C; Corcoran T; Bruck C; Thiriart C; Haigwood NL; Stott EJ
AIDS Res Hum Retroviruses; 1994 Oct; 10(10):1295-304. PubMed ID: 7848685
[TBL] [Abstract][Full Text] [Related]
17. Kinetic rates of antibody binding correlate with neutralization sensitivity of variant simian immunodeficiency virus strains.
Steckbeck JD; Orlov I; Chow A; Grieser H; Miller K; Bruno J; Robinson JE; Montelaro RC; Cole KS
J Virol; 2005 Oct; 79(19):12311-20. PubMed ID: 16160158
[TBL] [Abstract][Full Text] [Related]
18. Identification of two neutralizing and 8 non-neutralizing epitopes on simian immunodeficiency virus envelope using monoclonal antibodies.
Kent KA; Rud E; Corcoran T; Powell C; Thiriart C; Collignon C; Stott EJ
AIDS Res Hum Retroviruses; 1992 Jun; 8(6):1147-51. PubMed ID: 1380261
[TBL] [Abstract][Full Text] [Related]
19. N-linked glycosylation of the V3 loop and the immunologically silent face of gp120 protects human immunodeficiency virus type 1 SF162 from neutralization by anti-gp120 and anti-gp41 antibodies.
McCaffrey RA; Saunders C; Hensel M; Stamatatos L
J Virol; 2004 Apr; 78(7):3279-95. PubMed ID: 15016849
[TBL] [Abstract][Full Text] [Related]
20. Characterization and epitope mapping of neutralizing monoclonal antibodies produced by immunization with oligomeric simian immunodeficiency virus envelope protein.
Edinger AL; Ahuja M; Sung T; Baxter KC; Haggarty B; Doms RW; Hoxie JA
J Virol; 2000 Sep; 74(17):7922-35. PubMed ID: 10933700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
